katanin catalytic subunit A1 like 1Genealiases: []
Q-omics provides the consensus-scored KATNAL1 profile across patient tissues and cancer cell-line models. KATNAL1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KATNAL1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, KATNAL1 RNA expression shows 21,291 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where KATNAL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KATNAL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KATNAL1 survival associations across molecular data types. KATNAL1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KATNAL1 RNA expression–survival associations across cancer types. High KATNAL1 expression shows unfavorable associations in BLCA, LGG, ACC and LUSC, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KATNAL1 RNA expression.
This table summarizes KATNAL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KATNAL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KATNAL1 shows lower tumor expression in BLCA, KICH and LUSC and higher tumor expression in HNSC, KIRC and KIRP. The HNSC box plot shows higher KATNAL1 RNA expression in tumor versus normal tissue (log2 FC = +0.897, t-test p < 0.001).
This table shows molecular features associated with KATNAL1 in patient tissues and cancer cell lines. In patient samples, KATNAL1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KATNAL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
